GlassScriptPhysician profile
Melissa J Wolfe
NPI 1700123361
$614.20
in general payments reported to CMS, 2019-2025
16 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $164 · 2023: $111 · 2024: $176 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $136.60 | 2022-2024 | |
| Lilly USA, LLC | $90.58 | 2022-2025 | Mounjaro, Jardiance, Trulicity |
| Dexcom, INC. | $65.24 | 2022 | |
| Organon LLC | $59.08 | 2024 | |
| Amgen INC. | $44.99 | 2024-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $42.03 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.08 | 2024-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $17.48 | 2025 | Auvelity |
| Evofem Biosciences, INC. | $17.20 | 2022 | |
| Exact Sciences Corporation | $16.08 | 2025 | The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $15.82 | 2024 | Voquezna |
| Corcept Therapeutics | $14.83 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.11 | 2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $14.05 | 2023 | Breztri |
| Glaxosmithkline, LLC. | $13.76 | 2025 | Shingrix, Arexvy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $13.27 | 2024 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.